Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.37 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594827 | 0.84 | IRAK4 (0.38) | ALOX5APFEN1IRAK4LRRK2OPRK1 | |
| SCHEMBL28329731 | 0.82 | ALOX5AP (0.40) | ALOX5APFEN1IRAK4LRRK2PIK3CA | |
| SCHEMBL20269371 | 0.82 | IRAK4 (0.37) | ALOX5APFEN1IRAK4LRRK2OPRK1 | |
| SCHEMBL2838241 | 0.82 | LRRK2 (0.42) | IRAK4LRRK2OPRK1PIK3CA | |
| SCHEMBL14976692 | 0.78 | TBK1 (0.46) | LRRK2 | |
| SCHEMBL16036222 | 0.77 | RAF1 (0.47) | IRAK4LRRK2 | |
| SCHEMBL612648 | 0.77 | PIK3CA (0.46) | PIK3CA | |
| SCHEMBL17594656 | 0.76 | RAF1 (0.43) | ALOX5APFEN1IRAK4LRRK2OPRK1 | |
| SCHEMBL25931515 | 0.75 | BRD4 (0.36) | ALOX5APFEN1IRAK4LRRK2OPRK1 | |
| SCHEMBL26353117 | 0.75 | LRRK2 (0.40) | ALOX5APFEN1IRAK4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-10787443-B2 | RAF-degrading conjugate compounds | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-09-29 | — | — | US | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| EP-3615083-A1 | RAF-DEGRADING CONJUGATE COMPOUNDS | Quartz Therapeutics, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| CN-110545853-A | RAF degrading coupled compounds | QUARTZ THERAPEUTICS INC | 2019-12-06 | — | — | CN | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20180346457-A1 | RAF-DEGRADING CONJUGATE COMPOUNDS | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2018-12-06 | — | — | US | disclosed |
| WO-2018200981-A1 | RAF-DEGRADING CONJUGATE COMPOUNDS | QUARTZ THERAPEUTICS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9694016-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346457-A1 | RAF-DEGRADING CONJUGATE COMPOUNDS | BRAF, RAF1, ARAF | ALOX5AP 2961/4885FEN1 215/4885IRAK4 1772/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ALOX5AP 4001/4885FEN1 2809/4885IRAK4 610/4885 |
| US-20170260207-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALOX5AP 4001/4885FEN1 2809/4885IRAK4 610/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALOX5AP 4001/4885FEN1 2809/4885IRAK4 610/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | ALOX5AP 4001/4885FEN1 2809/4885IRAK4 610/4885 |
| US-10787443-B2 | RAF-degrading conjugate compounds | BRAF, RAF1, ARAF | ALOX5AP 2961/4885FEN1 215/4885IRAK4 1772/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | ALOX5AP 4001/4885FEN1 2809/4885IRAK4 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.